Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2018 2
2019 1
2021 4
2022 4
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Advanced and recurrent endometrial cancer: State of the art and future perspectives.
Tronconi F, Nero C, Giudice E, Salutari V, Musacchio L, Ricci C, Carbone MV, Ghizzoni V, Perri MT, Camarda F, Gentile M, Berardi R, Scambia G, Lorusso D. Tronconi F, et al. Among authors: perri mt. Crit Rev Oncol Hematol. 2022 Dec;180:103851. doi: 10.1016/j.critrevonc.2022.103851. Epub 2022 Oct 17. Crit Rev Oncol Hematol. 2022. PMID: 36257537 Review.
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S, Scambia G, Schettino C, Arenare L, Pisano C, Lombardi D, De Giorgi U, Andreetta C, Cinieri S, De Angelis C, Priolo D, Casanova C, Rosati M, Greco F, Zafarana E, Schiavetto I, Mammoliti S, Cecere SC, Salutari V, Scalone S, Farolfi A, Di Napoli M, Lorusso D, Gargiulo P, Califano D, Russo D, Spina A, De Cecio R, Chiodini P, Perrone F; MITO investigators. Pignata S, et al. Lancet Oncol. 2023 Mar;24(3):286-296. doi: 10.1016/S1470-2045(23)00016-5. Epub 2023 Feb 14. Lancet Oncol. 2023. PMID: 37052965 Clinical Trial.
Recent progress in the use of pharmacotherapy for endometrial cancer.
Giudice E, Salutari V, Ricci C, Nero C, Carbone MV, Musacchio L, Ghizzoni V, Perri MT, Camarda F, Tronconi F, Lorusso D, Scambia G. Giudice E, et al. Among authors: perri mt. Expert Opin Pharmacother. 2023 Jan;24(1):83-94. doi: 10.1080/14656566.2022.2106782. Epub 2022 Aug 5. Expert Opin Pharmacother. 2023. PMID: 35912837 Review.
Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data.
Agostinelli V, Musacchio L, Camarda F, Salutari V, Carbone MV, Ghizzoni V, Nero C, Ricci C, Perri MT, Giudice E, Lardino S, Berardi R, Scambia G, Lorusso D. Agostinelli V, et al. Among authors: perri mt. Cancer Manag Res. 2023 Sep 27;15:1063-1072. doi: 10.2147/CMAR.S294080. eCollection 2023. Cancer Manag Res. 2023. PMID: 37790898 Free PMC article. Review.
Lymph node staging in grade 1-2 endometrioid ovarian carcinoma apparently confined to the ovary: Is it worth?
Bizzarri N, Imterat M, Fruscio R, Giannarelli D, Perrone AM, Mancari R, Traut A, Rosati A, du Bois A, Ferrari D, De Iaco P, Ergasti R, Ataseven B, Bianchi T, Di Stanislao M, Perri MT, Heitz F, Concin N, Fanfani F, Vizza E, Scambia G, Harter P, Fagotti A. Bizzarri N, et al. Among authors: perri mt. Eur J Cancer. 2023 Dec;195:113398. doi: 10.1016/j.ejca.2023.113398. Epub 2023 Oct 20. Eur J Cancer. 2023. PMID: 37890354 Free article.
Gut microbiota and its influence on ovarian cancer carcinogenesis, anticancer therapy and surgical treatment: A literature review.
Giudice E, Salutari V, Ricci C, Nero C, Carbone MV, Ghizzoni V, Musacchio L, Landolfo C, Perri MT, Camarda F, Scambia G, Lorusso D. Giudice E, et al. Among authors: perri mt. Crit Rev Oncol Hematol. 2021 Dec;168:103542. doi: 10.1016/j.critrevonc.2021.103542. Epub 2021 Nov 18. Crit Rev Oncol Hematol. 2021. PMID: 34801701 Review.
17 results